Lumentum stock drops 5% in late morning trade as AI optics bets cool ahead of earnings

Lumentum stock drops 5% in late morning trade as AI optics bets cool ahead of earnings

New York, Jan 12, 2026, 11:53 AM ET — Regular session

  • Lumentum shares dropped roughly 5%, while the broader U.S. market hovered close to flat
  • Investors are focused on the company’s Feb. 3 earnings report and conference call
  • A recent SEC filing reveals a chief accounting officer change scheduled for early February

Lumentum Holdings shares dropped 5.4% to $332.28 in late-morning trading Monday, lagging behind a mostly flat U.S. market. The stock slipped $19.14 from its previous close and earlier dipped as low as $323.24.

This move is significant since Lumentum has become a swift, occasionally volatile stand-in for AI data center spending. The company sells optical components—the lasers and photonics that drive data through fiber—and that connection to cloud infrastructure projects has turned its stock into a hotspot for fast cash.

Lumentum will report fiscal second-quarter results on Feb. 3 after the market closes, the company announced. A webcast is scheduled for 5 p.m. ET that day. 1

Macro jitters also played a role. Investors started the week eyeing a U.S. Justice Department investigation involving Federal Reserve Chair Jerome Powell, a development that pushed funds into safe-haven assets Monday morning, Reuters reported. 2

The sector showed mixed action. Ciena dropped 1.4%, Coherent held steady, Nvidia remained flat, and Broadcom climbed roughly 1.3%.

Last week, Lumentum disclosed that its chief accounting officer, Matthew Sepe, will retire in fall 2026 and leave the position in early February. Eric Chang is set to replace him as chief accounting officer on that date. 3

Analysts remain fixated on AI-related capex despite the stock’s volatility. Mizuho’s Vijay Rakesh singled out Lumentum as a top pick for 2026, suggesting investors concerned about which chipmaker will come out on top might consider optical-networking firm Lumentum Holdings instead, Barron’s reported. 4

The stock’s valuation leaves barely any margin for error. Simply Wall St points to a widely cited fair value near $255 — well under the last closing price — and cautions that the narrative could unravel if orders from a handful of major cloud clients dip or if capacity bottlenecks persist. 5

Looking ahead, U.S. inflation figures and the kickoff of earnings season will dominate investor focus, Reuters reported. For those holding Lumentum, the Feb. 3 earnings release stands as the next major catalyst. 6

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Palantir stock edges up after Citi upgrade as Wall Street tests the AI trade again
Previous Story

Palantir stock edges up after Citi upgrade as Wall Street tests the AI trade again

Chevron stock edges up as U.S. flags Venezuela sanctions move; oil prices keep investors cautious
Next Story

Chevron stock edges up as U.S. flags Venezuela sanctions move; oil prices keep investors cautious

Go toTop